IOVS Proceedings of the National Academy of Sciences
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2003;44:2736-2742.)
© 2003 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.02-1160
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McGuire, P. G.
Right arrow Articles by Das, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGuire, P. G.
Right arrow Articles by Das, A.

The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by Å6 Suggests a New Therapeutic Target

Paul G. McGuire,1,2 Terence R. Jones,3 Nicholas Talarico,1 Erin Warren,1 and Arup Das1,2,4

1From the Departments of Cell Biology and Physiology and 2Surgery, University of New Mexico School of Medicine, Albuquerque, New Mexico; the 4New Mexico VA Health Care System, Albuquerque, New Mexico; and 3Ångstrom Pharmaceuticals Inc, San Diego, California.

PURPOSE. The objective of the study was to determine the role of urokinase (uPA) and the urokinase receptor (uPAR) in retinal angiogenesis, and whether loss of uPAR or the inhibition of uPA/uPAR interactions could suppress the extent of retinal neovascularization in an animal model of ischemic retinopathy.

METHODS. Retinal neovascularization was induced by exposing newborn mice to 75% oxygen on postnatal day 7 for 5 days, followed by exposure to room air on days 12 to 17. The expression of uPAR in the retina was investigated by RT-PCR and immunohistochemistry. The role of uPAR in ischemic retinopathy was investigated by quantitating the extent of retinal neovascularization in the uPAR-/- mouse. The effects of inhibiting the uPA/uPAR interaction on the development of retinal neovascularization were studied in this animal model with a uPA-derived peptide, Å6. Animals were treated with an intraperitoneal injection of Å6 at a dose of 5, 10, or 100 mg/kg once a day on days 12 to 16. Control animals included oxygen-exposed mice treated with similar amounts of PBS only on days 12 to 16. The effect of Å6 on the expression of uPAR in the retina was examined by real-time RT-PCR.

RESULTS. The expression of uPAR mRNA was upregulated in experimental animals during the period of angiogenesis and was localized to endothelial cells in the superficial layers of the retina. The uPAR-/- mouse demonstrated normal retinal vascular development; however, the absence of functional uPAR resulted in a significant reduction in the extent of retinal neovascularization. Histologic analysis of mice treated with Å6 peptide showed significant inhibition of retinal neovascularization, and the response was dose dependent. The RT-PCR analysis of the retinas of the Å6-treated animals showed a greater than twofold decrease in uPAR expression.

CONCLUSIONS. Expression of the urokinase receptor uPAR is essential to the development of retinal neovascularization. Inhibition of the activity of uPAR suppresses retinal neovascularization, possibly through a reduction in cell-associated proteolytic activity, cell signaling, or cell-matrix adhesion necessary for cell migration during angiogenesis. The uPA/uPAR interaction may be an important therapeutic target in the management of proliferative retinopathies.




This article has been cited by other articles:


Home page
 FASEB J.Home page
D. Navaratna, G. Menicucci, J. Maestas, R. Srinivasan, P. McGuire, and A. Das
A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes
FASEB J, September 1, 2008; 22(9): 3310 - 3317.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
D. Navaratna, J. Maestas, P. G. McGuire, and A. Das
Suppression of Retinal Neovascularization With an Antagonist to Vascular Endothelial Cadherin
Arch Ophthalmol, August 1, 2008; 126(8): 1082 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
I. Yamaguchi, J. M. Lopez-Guisa, X. Cai, S. J. Collins, D. M. Okamura, and A. A. Eddy
Endogenous urokinase lacks antifibrotic activity during progressive renal injury
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F12 - F19.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. S. Colombo, G. Menicucci, P. G. McGuire, and A. Das
Hepatocyte Growth Factor/Scatter Factor Promotes Retinal Angiogenesis through Increased Urokinase Expression
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1793 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
A. Das, N. Boyd, T. R. Jones, N. Talarico, and P. G. McGuire
Inhibition of Choroidal Neovascularization by a Peptide Inhibitor of the Urokinase Plasminogen Activator and Receptor System in a Mouse Model
Arch Ophthalmol, December 1, 2004; 122(12): 1844 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. J. Koh, K. Bessho, L. Cheng, D.-U. Bartsch, T. R. Jones, G. Bergeron-Lynn, and W. R. Freeman
Inhibition of Choroidal Neovascularization in Rats by the Urokinase-Derived Peptide A6
Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 635 - 640.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Association for Research in Vision and Ophthalmology